|Application ||WB, IHC, FC|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||39746 Da|
|Homology||Mouse - 12/14 amino acid residues identical; rat - 9/14 amino acid residues identical.|
|Other Names||C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, FB22, Fusin, HM89, LCR1, Leukocyte-derived seven transmembrane domain receptor, LESTR, Lipopolysaccharide-associated protein 3, LAP-3, LPS-associated protein 3, NPYRL, Stromal cell-derived factor 1 receptor, SDF-1 receptor, CD184, CXCR4|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)EGISIYTSDNYTEE, corresponding to amino acid residues 2-15 of human CXCR4 (Accession P61073). Extracellular, N-terminus.|
|Peptide Confirmation||Confirmed by amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Chemokines are small molecular weight, soluble secreted proteins that bind and activate their respective G-protein coupled receptor (GPCR), chemokine receptors in order to evoke a cellular response resulting in migration or chemotaxis1. The chemokine system involves more than 40 chemokines and 18 chemokine receptors. The receptors are designated CXCR1-5, CCR1-11, XCR1 and CX3CR1, based on their specific ligand preference2. Chemokine receptors are present on many different cell types. They were initially detected on leukocytes, where they were found to play an important role in the migration of these cells to inflammation sites3. CXCR4 was originally identified as an orphan receptor, and soon gained much attention when it was discovered as a coreceptor for HIV-14. Besides from being involved in HIV-1 infection/progression, CXCR4 is found to be upregulated in many different cancers/tumors and has evolved to become a target for the development of antagonists5. CXCL12 (SDF-1α) is the sole ligand for CXCR4. Following binding of its ligand, CXCR4 undergoes dimerization and activates Gi G-proteins6,7. However downstream activation through CXCR4 could also occur through other G-proteins and non-G-proteins5. The down regulation of the CXCR4 receptor is initiated by phosphorylation of its cytoplasmic tail, which is followed by the binding of arrestin. The receptor is then internalized through endocytosis and degraded in the lysosome. Downregulation of CXCR4 could also occur through the stimulation of other GPCRs8. The distribution of CXCR4 is quite broad and involves the central nervous system (CNS)9, spleen10, testes11, hematopoietic and non-hematopoietic cells2. Abgent is pleased to offer a highly specific antibody directed against an extracellular epitope of the human CXCR4. Anti-CXCR4 (extracellular) antibody (#AG1296) can be used for western blot analysis, immunohistochemistry and indirect flow cytometry applications. It was specifically designed to recognize rat, mouse and human CXCR4.
1. Raman, D. et al. (2007) Cancer Lett. 256, 137
2. Burger, J.A. and Kipps, T.J. (2006) Blood 107, 1761.
3. Loetscher, P. et al. (2000) Adv. Immunol. 74, 127.
4. Feng, Y. et al. (1996) Science 272, 872.
5. Wong, D. and Korz, W. (2008) Clin. Cancer. Res. 14, 7975.
6. Vila-Coro, A.J. et al. (1999) FASEB J. 13, 1699.
7. Holland, J.D. et al. (2006) Cancer Res. 66, 4117.
8. Richardson, R.M. et al. (2003) J. Biol. Chem. 278, 15867.
9. Zou, Y.R. et al. (1998) Nature 393, 595.
10. Heesen, M. et al. (1996) J. Immunol. 157, 5455.
11. Habasque, C. et al. (2002) Mol. Hum. Reprod. 8, 419.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.